|48.845 -0.075 (-0.15%)||11-29 11:02|
|Targets||6-month :||62.58||1-year :||66.3|
|Resists||First :||53.58||Second :||56.77|
|Supports||First :||48.41||Second :||40.28|
|MAs||MA(5) :||49.22||MA(20) :||50.55|
|MA(100) :||57.8||MA(250) :||64.9|
|MACD||MACD :||-1.6||Signal :||-1.6|
|%K %D||K(14,3) :||12.1||D(3) :||15.8|
|52-week||High :||81.44||Low :||48.41|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BMY ] has closed above bottom band by 25.6%. Bollinger Bands are 1.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||49.34 - 49.67||49.67 - 49.94|
|Low:||48.18 - 48.5||48.5 - 48.77|
|Close:||48.44 - 48.97||48.97 - 49.41|
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Wed, 29 Nov 2023
BMY Factor-Based Stock Analysis - Nasdaq
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||2,030 (M)|
|Shares Float||2,030 (M)|
|Held by Insiders||0 (%)|
|Held by Institutions||78.2 (%)|
|Shares Short||23,400 (K)|
|Shares Short P.Month||31,590 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||14.26|
|Profit Margin||18.4 %|
|Operating Margin||19.1 %|
|Return on Assets (ttm)||5.5 %|
|Return on Equity (ttm)||26.8 %|
|Qtrly Rev. Growth||-2.3 %|
|Gross Profit (p.s.)||17.92|
|Sales Per Share||22.13|
|Qtrly Earnings Growth||24 %|
|Operating Cash Flow||12,910 (M)|
|Levered Free Cash Flow||12,520 (M)|
|Price to Book value||3.43|
|Price to Sales||2.21|
|Price to Cash Flow||7.7|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|